Titre : | An injection depot formulation of buprenorphine: extended biodelivery and effects |
Auteurs : | S. C. SIGMON ; D. E. MOODY ; NUWAYSER E. S. ; G. E. BIGELOW |
Type de document : | Périodique |
Année de publication : | 2006 |
Format : | 420-432 / fig. ; tabl. |
Note générale : | Addiction, 2006, 101, (3), 420-432 |
Langues: | Anglais |
Discipline : | TRA (Traitement et prise en charge / Treatment and care) |
Mots-clés : |
Thésaurus mots-clés BUPRENORPHINE ; VOIE SOUSCUTANEE ; PHARMACOCINETIQUE ; EFFICACITE ; POSOLOGIE |
Résumé : | Aim: Buprenorphine is an effective medication for treatment of opioid dependence. An injectable depot formulation of buprenorphine has been developed using biodegradable polymer microcapsule technology. This formulation may offer effective treatment of opioid dependence and enhance treatment delivery while minimizing risks of patient non-adherence or illicit diversion of the medication. This report provides a characterization of the biodelivery of this injectable depot in humans and of the relationship of drug blood levels to pharmacodynamic indices. Method and participants: The data are from two studies in which 11 opioid-dependent volunteers each received a single depot injection containing 58 mg of buprenorphine, and include previously unreported detailed plasma concentration data over a 6-week time-course following depot administration and examination of their relationship to pharmacodynamic indices. Findings: Mean plasma buprenorphine increased gradually following depot administration, peaked at 23 days with a mean concentration of 1.25 ng/ml and then decreased gradually, approaching undetectable levels ( |
Domaine : | Drogues illicites / Illicit drugs |
Refs biblio. : | 53 |
Affiliation : | SATC-UHC, Room 1415, 1 South Prospect Street, Burlington, VT 05401, USA |
Numéro Toxibase : | 208841 |
Centre Emetteur : | 02 Coordonnateur |
Exemplaires
Disponibilité |
---|
aucun exemplaire |
Accueil